MML Investors Services
NAVB

MML Investors Services’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

MML Investors Services’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-700
Closed -$5K – 1449
2018
Q1 		$5K Buy
700
+125
+22% +$935 ﹤0.01% 1361
2017
Q4 		$4K Buy
575
+75
+15% +$635 ﹤0.01% 1388
2017
Q3 		$4K Buy
+500
New +$4.24K ﹤0.01% 1312

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MML Investors Services's NAVB Position: Q2 2018 in Review

MML Investors Services sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2018, closing a stake of 700 shares — an estimated $5K sold.

MML Investors Services first reported a position in NAVB in Q3 2017 and held it in 3 quarters. The position peaked at $5K in Q1 2018. 54 funds tracked by Wall St. Rank hold NAVB as of Q2 2018.

  • MML Investors Services reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • MML Investors Services sold 700 Navidea Biopharmaceuticals Inc. shares in Q2 2018, an estimated $5K.
  • MML Investors Services first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2017 and held it in 3 quarters.
  • MML Investors Services's Navidea Biopharmaceuticals Inc. position peaked at $5K in Q1 2018.
  • 54 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2018.

Based on MML Investors Services's 13F filing for Q2 2018, filed 13 Aug 2018.